Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Treatment of Childhood Nasopharyngeal Carcinoma With Neoadjuvant Chemotherapy and Concomitant Chemoradiotherapy
NCT00274937Phase 3Completed
- Sponsor
- Children's Oncology Group
- Start
- Feb 2006
- Primary completion
- Dec 2014
- Modality
- Nanoparticles, Small Molecules
- Countries
- 3
01
Overview
Phase 3, open-label trial of amifostine, Cisplatin micelle injection (HA132) and fluorouracil in nasopharyngeal carcinoma (NPC) (2 arms), sponsored by Children's Oncology Group. Primary endpoint: Event-free Survival at 2 years. Started Feb 2006; status: completed.
02
Drugs
amifostineCisplatin micelle injection (HA132)fluorouracil
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT00274937.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00274937.